Can a common diabetes drug shield transplanted kidneys?
NCT ID NCT04906213
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug empagliflozin (a diabetes medicine) in 20 people who had a kidney transplant, some with type 2 diabetes and some without. The goal was to see if the drug could help protect their heart and kidney function. The trial was stopped early, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Empagliflozin (a diabetes drug that helps protect the heart and kidneys)
- What this could lead to
- If it works, this could point toward a way to protect heart and kidney health in kidney transplant recipients, especially those with type 2 diabetes.
- What could go wrong
- This was a small, early-phase trial that was terminated early, so results are limited. The drug may increase the risk of urinary or genital infections in this population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a heart drug tame blood sugar and weight in diabetes?
- Can a vaccine shield transplant patients from shingles?
- Can a puff of insulin replace a needle for diabetes?
- Could a quick insulin shot stop Steroid-Induced blood sugar spikes?
- Can a puff of insulin replace a daily shot for diabetes?
- Could a Dairy-Rich diet tame type 2 diabetes?